nepafenac has been researched along with Endophthalmitis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hecht, I; Taipale, C; Tuuminen, R | 1 |
| Grzybowski, A; Kanclerz, P; Lytvynchuk, L | 1 |
| Christie, WC; Fong, R; Lehmann, RP; Modi, SS; Nethery, D; Philipson, B; Reiser, H; Roel, L; Sager, D; Traverso, CE; Tsorbatzoglou, A; Walters, TR | 1 |
| Bhardwaj, S; Lambat, S; Mehrotra, N; Nagpal, M; Paranjpe, G; Yadav, H | 1 |
| Kohnen, T | 1 |
| Bansal, R; Gupta, A; Pandav, SS; Ram, J; Sahu, S | 1 |
| Lane, SS | 1 |
1 review(s) available for nepafenac and Endophthalmitis
| Article | Year |
|---|---|
Nepafenac: a unique nonsteroidal prodrug.
Topics: Animals; Benzeneacetamides; Endophthalmitis; Humans; Ophthalmologic Surgical Procedures; Phenylacetates; Postoperative Complications; Prodrugs; Treatment Outcome | 2006 |
3 trial(s) available for nepafenac and Endophthalmitis
| Article | Year |
|---|---|
Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Double-Blind Method; Endophthalmitis; Eye Pain; Female; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Phenylacetates; Treatment Outcome; Young Adult | 2014 |
Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy.
Topics: Anti-Inflammatory Agents; Benzeneacetamides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endophthalmitis; Female; Humans; Male; Ophthalmic Solutions; Phenylacetates; Postoperative Complications; Prednisolone; Prodrugs; Prospective Studies; Sclera; Treatment Outcome; Visual Acuity; Vitrectomy | 2014 |
Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Endophthalmitis; Female; Humans; Intraocular Pressure; Ketorolac; Lens Implantation, Intraocular; Male; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Phenylacetates; Photometry; Postoperative Complications; Prospective Studies; Visual Acuity | 2015 |
3 other study(ies) available for nepafenac and Endophthalmitis
| Article | Year |
|---|---|
Clinical outcomes for measuring inflammatory response after cataract surgery.
Topics: Anti-Inflammatory Agents; Benzeneacetamides; Cataract Extraction; Endophthalmitis; Humans; Ophthalmic Solutions; Phenylacetates; Postoperative Complications; Prednisolone; Treatment Outcome | 2021 |
Methods for achieving low endophthalmitis rates in phacoemulsification cataract surgery.
Topics: Benzeneacetamides; Cataract; Endophthalmitis; Finland; Humans; Levofloxacin; Phacoemulsification; Phenylacetates; Prednisolone | 2020 |
Treating inflammation after lens surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Endophthalmitis; Humans; Ketorolac; Phacoemulsification; Phenylacetates; Postoperative Complications | 2015 |